Rock Springs Capital Management LP Immatics N.V. Transaction History

Rock Springs Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$10.23 - $12.94 $10.5 Million - $13.3 Million	-1,026,715 Reduced 54.74%	848,751 $8.92 Million
Q3 2023 Nov 14, 2023	SELL	$11.01 - $12.62 $7.27 Million - $8.34 Million	-660,678 Reduced 26.05%	1,875,466 $21.7 Million
Q2 2023 Aug 14, 2023	BUY	$5.92 - $12.72 $131,548 - $282,651	22,221 Added 0.88%	2,536,144 $29.3 Million
Q1 2023 May 15, 2023	BUY	$6.74 - $9.44 $1.61 Million - $2.26 Million	239,139 Added 10.51%	2,513,923 $17.3 Million
Q4 2022 Feb 14, 2023	BUY	$8.05 - $11.58 $4.78 Million - $6.87 Million	593,560 Added 35.31%	2,274,784 $19.8 Million
Q3 2022 Nov 14, 2022	BUY	$3.31 - $13.06 $1.83 Million - $7.23 Million	553,254 Added 49.05%	1,681,224 $16.8 Million
Q2 2022 Aug 15, 2022	BUY	$6.0 - $9.37 $6.77 Million - $10.6 Million	1,127,970 New	1,127,970 $9.83 Million

76.6M

571K

210K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $894M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.